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Abstract
Background: Limited studies have evaluated the medication-taking behavior in very elderly hypertensive patients.
The aim of this study was to evaluate the persistence and adherence with antihypertensive agents in treatment-
naïve patients, along with other related factors, according to age.
Methods: Adult (19–64 years), elderly (65–79 years), and very elderly (≥80 years) uncomplicated hypertensive
patients starting antihypertensive monotherapy were identified from the National Health Insurance claims database.
The first-year treatment persistence and adherence rates measured using the medication possession ratio were
assessed and compared in these three age cohorts.
Results: After propensity score matching, three age cohorts with 6689 patients each were assembled from 228,925
uncomplicated hypertensive patients who began antihypertensive monotherapy in 2012. The treatment persistence
and adherence rates over the first year were the lowest in the very elderly (59.5% and 62.8%, respectively) and highest
in the elderly (65.2% and 67.9%, respectively) patients among the three age cohorts (p < 0.001). The adjusted risk for
treatment non-persistence was significantly higher in the very elderly (adjusted hazard ratio, 1.20; 95% confidence
interval, 1.13–1.27) compared with the elderly. Having more comorbidities, being a beneficiary of medical aid, and
having a diagnosis of dementia were unique positive predictors for treatment persistence in the very elderly, along
with common predictors such as female sex, dyslipidemia, and an initially chosen antihypertensive therapeutic class
other than beta blockers and thiazide diuretics.
Conclusions: Very elderly patients were less likely to continue antihypertensive therapy over the first year compared
with their younger counterparts. Our findings suggest that a low comorbidity index and lack of medical aid support
negatively affect the treatment persistence in this population.
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Background
Hypertension is a major health problem worldwide and
requires long-term management and continuous ther-
apy. The prevalence among aged people is substantial;
approximately 80% of very elderly patients (defined as
those aged over 80 years) have been reported to have
hypertension [1]. Similarly, according to a report from
the National Health Service in England, the prevalence
of hypertension was 66.6% in the population aged over
75 years, as compared with 29.6% in the overall adult
populations in 2014 [2]. As the elderly population in-
creases (especially the very elderly population) [3], the
number of patients with chronic diseases requiring long-
term care is also increasing. As a result, the healthcare
expenditures are increasing worldwide, representing an
important social and public health issue [4].
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Effective management of hypertension in the elderly is
vital for preventing disease progression and related
comorbidities and for reducing health care costs [5, 6].
Although hypertension is a principal cause of cardiovascu-
lar and cerebrovascular events and is associated with in-
creased mortality [6, 7], before the publication of the
Hypertension in the Very Elderly Trial, the benefits of
treatment in very elderly patients with hypertension were
controversial. This trial confirmed that treatment of
hypertension reduced mortality even in the very elderly,
indicating its importance [8, 9].
Age has been considered a potential factor that can in-
fluence treatment persistence and adherence [10, 11],
and previous studies have mainly focused on elderly
populations [12, 13]. In 2008, van Wijk et al. measured
persistence with antihypertensive treatment in elderly
populations in the US, Canada, and the Netherlands,
and found similar patterns of persistence among the
three countries [12].
The patterns of medication persistence in Asian popu-
lation may differ from those in Western countries be-
cause of differences in race, healthcare systems, and
socioeconomic environment [14, 15]. Different racial
and ethnic groups show diverse perceptions and atti-
tudes towards health and medicines, which may affect
adherence to therapy [16]. Various reimbursement cov-
erages, drug prices, and financial barriers depending on
country-specific healthcare system and socioeconomic
environment have been reported to affect medication
persistence [14, 15, 17].
However, very few studies have evaluated hypertensive
treatment persistence and adherence in very elderly vs.
elderly hypertensive patients in Asia, including Korea. In
Korea, the National Health Insurance, a public insurance
program operated by the Ministry of Health and Wel-
fare, covers most of the Korean population claims data,
including patient data such as the diagnosis, prescription
medication, and medical costs, collected by each medical
institution. Using these nationwide healthcare claims
data in Korea, this study aimed to compare the antihy-
pertensive treatment persistence and adherence patterns
in very elderly patients with uncomplicated hypertension
to those of matched elderly and adult patients. In
addition, we also aimed to identify the factors associated
with non-persistence in the very elderly population.
Methods
Data source and cohort definition
For this retrospective cohort study, we used the Korean
National Health Insurance claims database from January
2011 to December 2013, provided by the Health Insur-
ance Review Agency following data anonymization.
We identified newly diagnosed uncomplicated hyper-
tensive adult patients who started antihypertensive
monotherapy in 2012. The index date was defined as
the date of the first antihypertensive prescription in
2012. Patients with a diagnosis code of hypertension
(International Classification of Diseases [ICD-10] codes
I10–13, I15) or who had been prescribed any antihyper-
tensive medication within 1 year before the index date were
excluded to ensure the inclusion of only treatment-naïve
hypertensive patients. Patients who had been previously di-
agnosed with the following comorbid conditions were also
excluded: cardiovascular disease (I20-I25, I30-I52, Z95),
cerebrovascular disease (G45, I60-I69), peripheral vascular
disease (I7X), renal disease (N03-N05, N18, N19, Z49,
Z94.0, Z99.2), diabetes mellitus (E08-E11, E13), and preg-
nancy (O00-O9A) [18]. In addition, to evaluate the patients’
medication-taking behavior, we excluded patients who had
been prescribed only one dose of antihypertensive medica-
tion or who had taken the medications for a period of less
than 7 days, as well as those who had been hospitalized for
more than 7 days within one year from the index date. The
patients were followed for one year from the index date
and were excluded if their claims data were discontinued
before the end of the follow-up period.
The patients were classified into three age categories:
adult (19–64 years), elderly (65–79 years), and very eld-
erly (≥80 years). The elderly and adult cohorts were con-
structed using propensity matching with common
reference cohorts of the very elderly [18]. The matching
variables included sex, the health insurance type, and
the Charlson Comorbidity Index [19]. The Charlson Co-
morbidity Index score, a prognostic comorbidity rating
score calculated based on 19 disease states each assigned
with a score of 1, 2, 3, or 6, corresponding to the risk of
mortality, was assessed using the ICD-10 codes to evalu-
ate the patient’s disease burden for 1 year before the
index date [19]. The prescribed antihypertensive medica-
tions used as the initial therapy were classified by their
therapeutic class: angiotensin receptor blockers (ARBs),
angiotensin converting enzyme inhibitors (ACEIs), se-
lective beta blockers (BBs), dihydropyridine calcium
channel blockers (CCBs), thiazide type diuretics (Ds),
alpha blockers (ABs), and others.
The study protocol was approved by the Institutional
Review Board (IRB) of Seoul National University (IRB
number: P01–201406-SB-03-02). A full ethical review
was made for all procedures following the protocol ap-
proved by the IRB. The board waived the need for in-
formed consent because only de-identified information
was used, without linkable data elements.
Treatment persistence and adherence
Treatment persistence was measured by the treatment
duration, defined as the number of days from the index
date to the discontinuation of any antihypertensive treat-
ment or the first appearance of a 60-day prescription gap.
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To assess treatment adherence, we used the medica-
tion possession ratio (MPR), calculated as the sum of
days covered by any antihypertensive medication one
year from the index date divided by 365 days. An MPR
≥0.8 was considered adherent [20].
To examine the patients’ age as a factor affecting treat-
ment non-persistence, we calculated the adjusted haz-
ards for treatment non-persistence for the very elderly
and elderly cohorts compared with the reference group
of adults. We also calculated the adjusted hazard for the
very elderly with elderly patients as the reference.
Factors associated with treatment non-persistence
We assessed the patient sex, Charlson Comorbidity
Index score, insurance type, specific underlying diseases
(dyslipidemia, dementia, and depression), and the initial
therapeutic class of the index therapy as factors poten-
tially affecting treatment non-persistence in the three
cohorts. The Charlson Comorbidity Index scores were
obtained using the diagnosis codes.
Statistical analysis
Demographic and clinical characteristics of the three co-
horts are presented with descriptive statistics, such as
the mean, standard deviation (SD), and percentage.
Comparisons of the continuous and discrete data among
the three cohorts were performed using analysis of vari-
ance (ANOVA) and chi-squared tests, respectively. We
considered a p value ≤0.05 to be statistically significant
and adjusted this value using Bonferroni correction.
The treatment persistence rates over the first year
stratified by the three cohorts were compared using the
log-rank test and are presented as adjusted Kaplan-
Meier curves. Multivariate Cox-proportional hazards
models were used to evaluate the influence of the poten-
tial risk factors on treatment non-persistence. The de-
gree of association is described by the adjusted hazard
ratio (aHR) and corresponding 95% confidence interval
(CI). Data management and statistical analyses were per-
formed using SAS 9.3 (SAS Institute, Inc., Cary, NC).
Results
Patient selection
We identified 228,925 uncomplicated, treatment-naïve
hypertensive patients who began antihypertensive mono-
therapy in 2012. After excluding patients who were
followed-up for less than one year (n = 9364), a total of
219,561 patients remained. Of these, 6803 patients
(3.1%) were classified as very elderly and 37,982 patients
(17.3%) as elderly. After propensity score matching for
sex, Charlson Comorbidity Index score, and health in-
surance type, 6689 patients were included in each of the
three cohorts.
Demographic and clinical characteristics
The mean (± SD) ages of the adult, elderly, and very eld-
erly cohorts were 50.4 (± 8.9), 70.9 (± 4.1), and 84.3 (±
4.0) years, respectively. Females comprised 72.6% of the
population in all three cohorts. The mean (± SD) Charl-
son Comorbidity Index score at baseline was 0.5 (± 0.9),
and 7.2% of all patients were receiving medical aid. The
number of concomitant medications was the highest in
the very elderly cohort and lowest in the adult cohort
(p < 0.05). Compared with the other two cohorts, the
very elderly cohort had the highest proportion of de-
mentia patients and lowest proportion of patients with
dyslipidemia (p < 0.0001). Depression was more preva-
lent in the adult cohort than in the other cohorts
(p < 0.0001). Overall, the most frequent therapeutic class
of index therapy was CCBs (48.9%), followed by ARBs
(32.0%), BBs (10.0%), and Ds (6.0%). While this trend
was also observed in the very elderly and elderly cohorts
individually, ARBs were somewhat more prevalent than
CCBs in the adult cohort (Table 1).
Treatment persistence and adherence
The very elderly cohort showed a significantly shorter
treatment duration than the other two cohorts (p < 0.05,
Table 2). Although similar proportions of patients con-
tinued antihypertensive treatment after the first three
months, the proportion of patients who remained on
any antihypertensive treatment at the end of the first
year was significantly lower in the very elderly cohort
(59.5%) than in the elderly cohort (65.2%, p < 0.001).
Adjusted Kaplan-Meier analysis of the treatment persist-
ence rate over the first year also revealed lower treat-
ment persistence in the very elderly cohort compared to
in the other two cohorts (Fig. 1).
The adherence rate over one year showed a similar
pattern, with the lowest rate observed in the very elderly
cohort (62.8% vs. 64.1% and 67.9% in the adult and eld-
erly cohorts, respectively, p < 0.001 for both) (Table 2).
After adjusting for sex, insurance type, comorbidities,
underlying disease, and initial therapeutic class of index
therapy, the likelihood of discontinuing antihypertensive
treatment was significantly higher in the very elderly pa-
tients (aHR, 1.20; 95% CI, 1.13–1.27) compared with in
the elderly patients. However, the adjusted risk of treat-
ment non-persistence in the very elderly (aHR, 0.99;
95% CI, 0.94–1.05) was similar to that of adults (aHR,
0.99; 95% confidence interval (CI), 0.94–1.05), while eld-
erly patients exhibited a significantly lower risk than
adults (aHR, 0.84; 95% CI, 0.79–0.89).
Predictors of treatment non-persistence
Table 3 shows the predictors of treatment non-
persistence in the three cohorts. Although the pres-
ence of comorbidities was not significantly associated
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with treatment persistence in uncomplicated adult or
elderly hypertensive patients, patients with at least
one comorbidity were more likely to continue treat-
ment in the very elderly cohort (aHR, 0.93; 95% CI,
0.87–0.98). Among the very elderly, patients who
received medical aid were more likely to persist with
the treatment (aHR, 0.83; 95% CI, 0.71–0.98), while
in the adult cohort, those receiving medical aid were
at higher risk of non-persistence (aHR, 1.21; 95% CI,
1.06–1.39). Patients with dementia showed a lower











Age, years, mean (SD) 68.5 (15.2) 50.4 (9.0) 70.9 (4.1) 84.3 (4.0) <0.0001 a < b < c
Sex, male, n (%) 5502 (27.4) 1834 (27.4) 1834 (27.4) 1834 (27.4) 1.000
Charlson comorbidity
index score, mean (SD)
0.5 (0.9) 0.5 (0.9) 0.5 (0.8) 0.5 (0.9) 0.948
0 12,780 (63.7) 4258 (63.7) 4264 (63.8) 4258 (63.7) 1.000
≥ 1 7287 (36.3) 2431 (36.3) 2425 (36.3) 2431 (36.3) 0.992
Health insurance type
Health insurance 18,621 (92.8) 6207 (92.8) 6207 (92.8) 6207 (92.8) 1
Medical aid 1446 (7.2) 482 (7.2) 482 (7.2) 482 (7.2)
Number of concomitant
medications, mean (SD)
3.3 (2.8) 2.7 (2.4) 3.4 (2.8) 3.7 (3.0) <0.0001 a < b < c
Underlying disease, n (%)
Dementia 277 (2.1) 24 (0.2) 59 (0.9) 194 (2.9) <0.0001 a < b < c
Depression 639 (4.6) 440 (3.2) 104 (1.6) 95 (1.4) <0.0001 a > b,c
Dyslipidemia 2496 (16.3) 1963 (12.8) 366 (5.5) 167 (2.5) <0.0001 a > b > c
Therapeutic class of index therapy, n (%)
Dihydropyridine calcium channel
blockers
9807 (48.9) 2619 (39.2) 3374 (50.4) 3814 (57.0) <0.0001 <0.0001
Angiotensin receptor blockers 6419 (32.0) 2722 (40.7) 2077 (31.1) 1620 (24.2)
Selective beta blockers 2009 (10.0) 900 (13.5) 620 (9.3) 489 (7.3)
Thiazide type diuretics 1212 (6.0) 324 (4.8) 412 (6.2) 476 (7.1)
Alpha blockers 359 (1.8) 29 (0.4) 128 (1.9) 202 (3.0)
Angiotensin converting enzyme
inhibitors
250 (1.2) 84 (1.3) 78 (1.2) 88 (1.3)
Others 11 (0.1) 11 (0.2) 0 (0.0) 0 (0.0)
*Analysis of variance test or chi-squared test of the three groups
†Bonferroni correction (p < 0.015) with student’s t-test or chi-squared test
aAdult cohort bElderly cohort cVery elderly cohort
Table 2 Comparison of treatment persistence and adherence among propensity-matched cohorts
Variables Adults a (n = 6689) Elderly b (n = 6689) Very elderly c (n = 6689) p-value* Post hoc†
Treatment duration, days, mean (SD) 277.1 (122.8) 280.6 (123.3) 267.6 (127.2) <0.0001 a,b > c
Treatment persistence rate, n (%)
at the first 3 months 5753 (86.0) 5764 (86.2) 5663 (84.7) 0.024 b > c
at the first 6 months 4731 (70.7) 4754 (71.1) 4473 (66.9) <0.0001 a, b > c
at the first 9 months 4422 (66.1) 4532 (67.8) 4207 (62.9) <0.0001 a, b > c
at the first 12 months 4179 (62.5) 4364 (65.2) 3979 (59.5) <0.0001 b > a > c
Medication possession ratio, mean (SD) 0.76 (0.30) 0.79 (0.29) 0.75 (0.30) <0.0001 b > a, c
Treatment adherence rate, n (%) 4290 (64.1) 4542 (67.9) 4135 (62.8) <0.0001 b > a > c
*Analysis of variance test or chi-squared test of the three groups
†Bonferroni correction (p < 0.015) with student’s t-test or chi-squared test
aAdult cohort bElderly cohort cVery elderly cohort
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risk of discontinuing treatment only in the very eld-
erly cohort (aHR, 0.68; 95% CI, 0.52–0.90). Finally,
in terms of the initial therapeutic classes of drugs,
only Ds and BBs were associated with treatment
non-persistence in elderly and very elderly patients
(Table 3).
Discussion
To our knowledge, this is the first nationwide population-
based study focused on antihypertensive medication per-
sistence and adherence in a very elderly population at the
time of initiation of antihypertensive monotherapy in
Korea. We found that very elderly patients were more
likely to discontinue antihypertensive treatment than eld-
erly or adult patients, and that the predictors of treatment
non-persistence in the very elderly differed from those in
the other age groups. The one-year treatment persistence
rate in very elderly patients was significantly lower than
that in elderly patients (59.5% vs. 65.2%, p < 0.001); after
adjustment for potential confounding variables, very eld-
erly patients remained at elevated risk of treatment non-
persistence compared with elderly patients (aHR, 1.20;
95% CI, 1.13–1.27). Despite the statistically significant dif-
ferences in treatment persistence and adherence among
Fig. 1 Treatment persistence rate over the first year among adult,
elderly and very elderly cohorts (n = 20,067). Green line: adults (19–
64 years); Red line: elderly (65–79 years); Blue line: very
elderly (≥80 years)
Table 3 Predictors for antihypertensive treatment non-persistence in three propensity-matched cohorts a
Characteristics Adults (n = 6689) Elderly (n = 6689) Very elderly (n = 6689)
aHR 95% CI aHR 95% CI aHR 95% CI
Sex
Male (reference) 1.00 1.00 1.00
Female 0.90 0.82–0.98 0.92 0.84–1.01 0.85 0.78–0.93
Charlson comorbidity index score
0 (reference) 1.00 1.00 1.00
≥ 1 0.95 0.87–1.03 0.98 0.92–1.04 0.93 0.87–0.98
Health insurance type
Health insurance (reference) 1.00 1.00 1.00
Medical aid 1.21 1.06–1.39 1.07 0.92–1.26 0.83 0.71–0.98
Underlying disease risk factor
Dementia 1.66 0.93–2.97 1.15 0.75–1.77 0.68 0.52–0.90
Depression 1.11 0.95–1.28 1.36 1.00–1.85 0.91 0.63–1.32
Dyslipidaemia 0.64 0.59–0.71 0.75 0.61–0.92 0.75 0.57–0.98
Therapeutic class of index therapy
Angiotensin receptor blockers (reference) 1.00 1.00 1.00
Dihydropyridine calcium channel blockers 1.12 1.02–1.22 1.03 0.93–1.13 1.04 0.94–1.14
Selective beta blockers 1.93 1.73–2.16 1.58 1.37–1.82 1.29 1.11–1.51
Thiazide diuretics 4.04 3.49–4.67 2.87 2.48–3.33 1.74 1.51–2.02
Alpha blockers 1.90 1.15–3.15 1.23 0.92–1.65 1.03 0.81–1.30
Angiotensin converting enzyme inhibitors 1.42 1.03–1.97 1.14 0.77–1.68 0.96 0.68–1.37
Others 2.39 1.18–4.88
Abbreviations: aHR adjusted hazard ratio; CI confidence interval
aPredictors for antihypertensive treatment non-persistence were identified using a multivariate Cox-proportional Hazard model
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the three age cohorts, the one-year treatment adherence
was more than 60% in all three groups. These results cor-
roborate the findings from other studies conducted in
Western countries [12, 13]. In 2008, van Wijk et al. re-
ported that approximately 25% of elderly patients studied
were non-persistent, defined as a treatment gap of at least
180 days during the first year of treatment, with little dif-
ference among the three examined countries (the US,
Canada, and the Netherlands) [12]. In 2014, Tu et al.
found that 64.6% of elderly patients in Canada were
therapy-persistent for over one year [13].
The present study found that elderly patients aged 65–
79 years were more persistent with antihypertensive treat-
ment than adults, while the very elderly showed poor
treatment persistence. This result is consistent with previ-
ously published results from Canada [13] and Sweden
[21], which showed reduced odds of medication persist-
ence in patients older than 75 years compared to those
aged 66–70 years. However, other previous studies that
have investigated the impact of aging on treatment persist-
ence have reached conflicting results [22, 23]. These dis-
crepancies may be partially explained by differences in age
composition, reference groups, and methodology used in
measuring persistence, such as a prescription gap, be-
tween the studies.
Unlike in previous studies, the present study included
only uncomplicated hypertensive patients. Therefore, the
Charlson Comorbidity Index score was low, and two-
thirds of the study patients had no comorbid conditions.
The findings from previous studies investigating comor-
bidities as a risk factor for treatment non-persistence
have been inconsistent [13, 23]. In the present investiga-
tion, we found that patients with one or more comorbid-
ities were significantly more likely to remain treatment
persistent than those without a comorbidity in the very
elderly population, whereas the presence of comorbidi-
ties did not predict poor persistence in adults or in the
elderly. These findings may be explained by the fact that
very elderly patients with comorbidities might be more
likely to continue hypertensive treatment because they
require regular visits to healthcare facilities for diseases
other than hypertension. Furthermore, in the very eld-
erly population, patients with comorbidities might be
more likely to continue hypertensive treatment because
they require regular visits to healthcare facilities for dis-
eases other than hypertension.
Beneficiaries of medical aid receive prescription drugs
free of charge in Korea. Accordingly, in our study, being
a beneficiary of medical aid was positively associated
with treatment persistence in the very elderly cohort
(aHR, 0.83; 95% CI, 0.71–0.98). This finding is consistent
with those of several studies that reported sufficient
health insurance or prescription drug coverage as the
principal contributing factor to treatment persistence
[10, 14, 24]. On the other hand, in our study, the insur-
ance type was negatively associated with treatment per-
sistence in the adult cohort (aHR: 1.21; 95% CI: 1.06–
1.39). This finding may be explained by the difference in
eligibility for medical aid between the adult and very eld-
erly populations in Korea. Adults who receive medical
aid in Korea tend to have a very low economic status,
which is a recognized risk factor for lower treatment
persistence [14, 25].
Moreover, very elderly patients diagnosed with demen-
tia or dyslipidemia were significantly more likely to re-
main persistent with antihypertensive treatment. The
finding of the association between dyslipidemia and
treatment persistence corroborates a number of pub-
lished studies [12, 23, 25, 26]. However, our finding of
higher persistence in very elderly patients with dementia
contrasts with the results from several previous studies
reporting a higher discontinuation rate for antihyperten-
sive treatment among patients with dementia or cogni-
tive impairment [27, 28]. These contradictory findings
are somewhat puzzling, and may be partially explained
by the lower medication complexity in older adults with
cognitive impairment, as observed in one previous study
[29]. The care management by caregivers may also in-
crease the treatment persistence in the very elderly with
dementia [30], which is supported by the findings of re-
cent studies that dementia was associated with the likeli-
hoods of continuing statin therapy (aHR, 0.84; 95% CI,
0.73–0.98) and antiplatelet therapy in elderly patients
after ischemic stroke [31, 32].
Ds and BBs as initial antihypertensives were negatively
associated with treatment persistence, as compared with
ARBs, in the very elderly cohort, whereas the rate of
non-persistence in the adult cohort was slightly but sig-
nificantly higher for CCB, AB, and ACEI initiators, as
well as BB and D initiators, as compared with ARB initi-
ators. The Eighth Joint National Committee guidelines
do not recommend BBs for initial hypertensive therapy
due to the relatively high risks of cardiovascular death,
myocardial infarction, and stroke with these agents. In
addition, the Canadian Institute for Health Information
reported that Ds associate with the lowest persistence
when newly prescribed in patients over 65 years of age
[33, 34]. Marcum et al. analyzed the rate of
hospitalization from adverse drug reactions in older vet-
erans and found that BBs and Ds were associated with
significantly elevated rates [35]. Thus, the low persist-
ence commonly observed in elderly and very elderly pa-
tients when beginning a BB or D may stem from the
higher risk of adverse drug reactions from these antihy-
pertensive classes.
The increased risk of adverse drug events and incon-
sistency in the efficacy associated with changes in phar-
macokinetic and pharmacodynamic profiles with aging
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also may negatively affect drug persistence particularly
in the very elderly compared with the elderly patients
[36, 37].
Some limitations should be considered when interpret-
ing our findings. First, due to the nature of retrospective
claims data, we could not confirm whether the patients
actually took the medications that were prescribed.
Therefore, our study likely overestimated the actual
treatment adherence and persistence. Second, the study
only included patients who started monotherapy for un-
complicated hypertension. We excluded patients who
began combination therapy in order to minimize con-
founding by disease severity, which could not be reliably
measured in our cohort. Therefore, our results may not
be generalizable to patients administered combination
therapy. Finally, while we measured the health insurance
type as a marker of socioeconomic position, we could
not consider other important socioeconomic variables
due to limitations of the claims data.
Conclusions
This study showed that very elderly patients were more
likely to discontinue antihypertensive treatment when
compared with elderly patients; approximately 40% of very
elderly uncomplicated hypertensive patients were treat-
ment non-persistent during the first year. In addition, this
study suggests that a low comorbidity index and lack of
medical aid support negatively affect the treatment per-
sistence uniquely in this population.
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